Phosphodiesterase Type 5 Inhibition to Improve Endothelial Function and Vascular Remodeling in Chronic Kidney Disease and End Stage Renal Disease Patients Requiring New Arteriovenous Fistula
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 15 Mar 2018
At a glance
- Drugs Sildenafil (Primary)
- Indications Renal failure; Vascular restenosis
- Focus Therapeutic Use
- 12 Mar 2018 Planned End Date changed from 1 Jan 2018 to 1 Jun 2018.
- 06 Jul 2017 Planned End Date changed from 1 Nov 2017 to 1 Jan 2018.
- 06 Jul 2017 Status changed from recruiting to active, no longer recruiting.